These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 22118358)

  • 21. Mortality in men with localized prostate cancer treated with brachytherapy with or without neoadjuvant hormone therapy.
    Dosoretz AM; Chen MH; Salenius SA; Ross RH; Dosoretz DE; Katin MJ; Mantz C; Nakfoor BM; D'Amico AV
    Cancer; 2010 Feb; 116(4):837-42. PubMed ID: 20052734
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Quality of life after radiotherapy for prostate cancer].
    Joly F; Degrendel AC; Guizard AV
    Cancer Radiother; 2010 Oct; 14(6-7):519-25. PubMed ID: 20728393
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Health-related quality of life in men receiving prostate brachytherapy on RTOG 98-05.
    Feigenberg SJ; Lee WR; Desilvio ML; Winter K; Pisansky TM; Bruner DW; Lawton C; Morton G; Baikadi M; Sandler H
    Int J Radiat Oncol Biol Phys; 2005 Jul; 62(4):956-64. PubMed ID: 15989995
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Early quality of life assessment in men treated with permanent source interstitial brachytherapy for clinically localized prostate cancer.
    Lee WR; McQuellon RP; Case LD; deGuzman AF; McCullough DL
    J Urol; 1999 Aug; 162(2):403-6. PubMed ID: 10411047
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of low dose-rate prostate brachytherapy on the sexual health of men with optimal sexual function before treatment: analysis at > or = 7 years of follow-up.
    Cesaretti JA; Kao J; Stone NN; Stock RG
    BJU Int; 2007 Aug; 100(2):362-7. PubMed ID: 17617140
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Permanent 125I-seed brachytherapy or radical prostatectomy: a prospective comparison considering oncological and quality of life results.
    Borchers H; Kirschner-Hermanns R; Brehmer B; Tietze L; Reineke T; Pinkawa M; Eble MJ; Jakse G
    BJU Int; 2004 Oct; 94(6):805-11. PubMed ID: 15476513
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Erectile function durability following permanent prostate brachytherapy.
    Taira AV; Merrick GS; Galbreath RW; Butler WM; Wallner KE; Kurko BS; Anderson R; Lief JH
    Int J Radiat Oncol Biol Phys; 2009 Nov; 75(3):639-48. PubMed ID: 19303721
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prospective assessment of patient-reported long-term urinary morbidity and associated quality of life changes after 125I prostate brachytherapy.
    Stone NN; Stock RG
    Brachytherapy; 2003; 2(1):32-9. PubMed ID: 15062161
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Survivorship beyond convalescence: 48-month quality-of-life outcomes after treatment for localized prostate cancer.
    Gore JL; Kwan L; Lee SP; Reiter RE; Litwin MS
    J Natl Cancer Inst; 2009 Jun; 101(12):888-92. PubMed ID: 19509365
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Promising long-term health-related quality of life after high-dose-rate brachytherapy boost for localized prostate cancer.
    Wahlgren T; Nilsson S; Lennernäs B; Brandberg Y
    Int J Radiat Oncol Biol Phys; 2007 Nov; 69(3):662-70. PubMed ID: 17499452
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The effect of brachytherapy, external beam irradiation and hormonal therapy on prostate volume.
    Stone NN; Stock RG
    J Urol; 2007 Mar; 177(3):925-8. PubMed ID: 17296377
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical and physical determinants for toxicity of 125-I seed prostate brachytherapy.
    Wust P; von Borczyskowski DW; Henkel T; Rosner C; Graf R; Tilly W; Budach V; Felix R; Kahmann F
    Radiother Oncol; 2004 Oct; 73(1):39-48. PubMed ID: 15465144
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The 1999 patterns of care study of radiotherapy in localized prostate carcinoma: a comprehensive survey of prostate brachytherapy in the United States.
    Lee WR; Moughan J; Owen JB; Zelefsky MJ
    Cancer; 2003 Nov; 98(9):1987-94. PubMed ID: 14584083
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [The chronological process of erectile function after low-dose rate prostate brachytherapy for localised prostate cancer].
    Bannowsky A; Bäurle L; Ataniyasov R; Ahlen Hv; Loch T
    Aktuelle Urol; 2011 Jul; 42(4):252-5. PubMed ID: 21769761
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The effect of high dose rate brachytherapy in combination with external beam radiotherapy on men's health-related quality of life and sexual function over a 2 year time span.
    Conaglen HM; de Jong D; Hartopeanu C; Conaglen JV; Tyrie LK
    Clin Oncol (R Coll Radiol); 2013 Mar; 25(3):197-204. PubMed ID: 23183305
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Health-related quality of life up to six years after (125)I brachytherapy for early-stage prostate cancer.
    Roeloffzen EM; Lips IM; van Gellekom MP; van Roermund J; Frank SJ; Battermann JJ; van Vulpen M
    Int J Radiat Oncol Biol Phys; 2010 Mar; 76(4):1054-60. PubMed ID: 20097486
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Variations in international prostate symptom scores, uroflowmetric parameters, and prostate volume after (125)I permanent brachytherapy for localized prostate cancer.
    Tanaka N; Fujimoto K; Hirao Y; Asakawa I; Hasegawa M; Konishi N
    Urology; 2009 Aug; 74(2):407-11. PubMed ID: 19376570
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Single-fraction high-dose-rate brachytherapy and hypofractionated external beam radiotherapy for men with intermediate-risk prostate cancer: analysis of short- and medium-term toxicity and quality of life.
    Morton GC; Loblaw DA; Sankreacha R; Deabreu A; Zhang L; Mamedov A; Cheung P; Keller B; Danjoux C; Szumacher E; Thomas G
    Int J Radiat Oncol Biol Phys; 2010 Jul; 77(3):811-7. PubMed ID: 19836166
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Health-related quality of life after permanent I-125 brachytherapy and conformal external beam radiotherapy for prostate cancer--a matched-pair comparison.
    Pinkawa M; Asadpour B; Piroth MD; Gagel B; Nussen S; Kehl M; Borchers H; Jakse G; Eble MJ
    Radiother Oncol; 2009 May; 91(2):225-31. PubMed ID: 19081154
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Clinical outcome of intermediate risk prostate cancer treated with iodine 125 monotherapy: The Hotel-Dieu of Quebec experience].
    Zebentout O; Apardian R; Beaulieu L; Harel F; Martin AG; Vigneault E
    Cancer Radiother; 2010 Jun; 14(3):183-8. PubMed ID: 20418145
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.